NUVL

Nuvalent Inc

NUVL, USA

Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

https://www.nuvalent.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
NUVL
stock
NUVL

UBS reiterates Buy rating on Nuvalent stock, citing Royalty Pharma deal Investing.com

Read more →
NUVL
stock
NUVL

Nuvalent’s Royalty Interest Acquired by Royalty Pharma TipRanks

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$141.8235

Analyst Picks

Strong Buy

8

Buy

3

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Neutral

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

8.77

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-14.48 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-12.49 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.16

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 106.26% of the total shares of Nuvalent Inc

1.

Deerfield Management Co

(24.9512%)

since

2025/06/30

2.

FMR Inc

(13.8255%)

since

2025/06/30

3.

Paradigm Biocapital Advisors LP

(7.308%)

since

2025/06/30

4.

Vanguard Group Inc

(6.2744%)

since

2025/06/30

5.

BlackRock Inc

(5.6116%)

since

2025/06/30

6.

Fidelity Growth Compy Commingled Pl S

(3.3827%)

since

2025/07/31

7.

T. Rowe Price Associates, Inc.

(2.4899%)

since

2025/06/30

8.

HHG PLC

(2.4722%)

since

2025/06/30

9.

Fidelity Growth Company Fund

(2.3788%)

since

2025/07/31

10.

Wellington Management Company LLP

(2.1862%)

since

2025/06/30

11.

State Street Corp

(2.0668%)

since

2025/06/30

12.

Vanguard Total Stock Mkt Idx Inv

(2.0313%)

since

2025/07/31

13.

Bain Capital Life Sciences Investors, LLC

(2.0072%)

since

2025/06/30

14.

Perceptive Advisors LLC

(1.9072%)

since

2025/06/30

15.

COMMODORE CAPITAL LP

(1.9069%)

since

2025/06/30

16.

JPMorgan Chase & Co

(1.6603%)

since

2025/06/30

17.

BRAIDWELL LP

(1.6308%)

since

2025/06/30

18.

Vanguard Small Cap Index

(1.5646%)

since

2025/07/31

19.

T. Rowe Price Investment Management,Inc.

(1.518%)

since

2025/06/30

20.

Vestal Point Capital LP

(1.4909%)

since

2025/06/30

21.

iShares Russell 2000 ETF

(1.4363%)

since

2025/08/31

22.

Geode Capital Management, LLC

(1.3825%)

since

2025/06/30

23.

Woodline Partners LP

(1.2541%)

since

2025/06/30

24.

Polar Capital Holdings PLC

(1.1318%)

since

2025/06/30

25.

Fairmount Funds Management LLC

(1.009%)

since

2025/06/30

26.

Vanguard Small Cap Value Index Inv

(1.0085%)

since

2025/07/31

27.

Fidelity Select Health Care

(0.9733%)

since

2025/07/31

28.

JPMorgan Mid Cap Growth I

(0.9013%)

since

2025/07/31

29.

Polar Capital Biotech S Inc

(0.8668%)

since

2025/07/31

30.

SPDR® S&P Biotech ETF

(0.8191%)

since

2025/08/31

31.

Vanguard Health Care Inv

(0.7412%)

since

2025/06/30

32.

Fidelity Growth Company K6

(0.7287%)

since

2025/07/31

33.

US Small-Cap Growth II Equity Comp

(0.7168%)

since

2025/06/30

34.

Fidelity Small Cap Growth

(0.7111%)

since

2025/06/30

35.

T. Rowe Price New Horizons

(0.6907%)

since

2025/07/31

36.

T. Rowe Price US Small-Cap Core Equity

(0.6802%)

since

2025/06/30

37.

Fidelity Series Growth Company

(0.6623%)

since

2025/07/31

38.

T. Rowe Price Small-Cap Stock

(0.6514%)

since

2025/07/31

39.

JPM US Mid Cap Growth-Composite

(0.6283%)

since

2025/06/30

40.

Fidelity Small Cap Index

(0.5978%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-1.38

Latest Release

Date

2025-09-30

EPS Actual

-1.7

EPS Estimate

-1.36

EPS Difference

-0.34

Surprise Percent

-25%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(3.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(3)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.